A single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSI-953 in blood and cerebrospinal fluid, when administered orally to healthy young subjects and patients with Alzheimer disease

Trial Profile

A single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSI-953 in blood and cerebrospinal fluid, when administered orally to healthy young subjects and patients with Alzheimer disease

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Begacestat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jul 2008 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 09 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top